TG Therapeutics Inc. (TGTX) Receives Consensus Rating of “Buy” from Brokerages
TG Therapeutics Inc. (NASDAQ:TGTX) has been given an average recommendation of “Buy” by the eight brokerages that are currently covering the company. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $21.90.
Several equities research analysts recently weighed in on the stock. Brean Capital reaffirmed a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Thursday, October 6th. FBR & Co reissued a “buy” rating on shares of TG Therapeutics in a report on Monday, September 19th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price (down previously from $22.00) on shares of TG Therapeutics in a report on Saturday, October 15th. Ladenburg Thalmann reissued a “buy” rating and issued a $28.00 target price on shares of TG Therapeutics in a report on Saturday, October 15th. Finally, Roth Capital reissued a “buy” rating and issued a $33.00 target price on shares of TG Therapeutics in a report on Friday, October 14th.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/26/tg-therapeutics-inc-tgtx-receives-consensus-rating-of-buy-from-brokerages.html.
A number of hedge funds and other institutional investors have recently modified their holdings of TGTX. Price T Rowe Associates Inc. MD acquired a new position in shares of TG Therapeutics during the third quarter worth about $114,000. BlackRock Group LTD raised its position in shares of TG Therapeutics by 2.9% in the third quarter. BlackRock Group LTD now owns 17,779 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 504 shares during the period. BlackRock Advisors LLC raised its position in shares of TG Therapeutics by 14.5% in the second quarter. BlackRock Advisors LLC now owns 18,131 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 2,296 shares during the period. Mariner Wealth Advisors LLC raised its position in shares of TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 800 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of TG Therapeutics during the third quarter worth about $199,000. Institutional investors and hedge funds own 54.27% of the company’s stock.
TG Therapeutics (NASDAQ:TGTX) opened at 5.80 on Monday. The company’s 50-day moving average is $6.13 and its 200-day moving average is $6.63. The firm’s market cap is $317.44 million. TG Therapeutics has a one year low of $4.90 and a one year high of $14.87.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.19. TG Therapeutics had a negative return on equity of 83.18% and a negative net margin of 47,494.08%. On average, analysts forecast that TG Therapeutics will post ($1.41) earnings per share for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Stock Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related stocks with our FREE daily email newsletter.